骨性关节炎模型大鼠关节软骨变化及透骨消痛胶囊干预的作用  

Effect of Tougu Xiaotong capsule on articular cartilage changes in rat models of osteoarthritis

作　　者：吴广文[1] 叶锦霞[1] 郑春松[1] 陈文列[1] 刘献祥[1] 叶蕻芝[1] 

机构地区：[1]福建中医药大学中西医结合研究院,福建省福州市350122

出　　处：《中国组织工程研究》2014年第49期7924-7929,共6页Chinese Journal of Tissue Engineering Research

基　　金：国家自然科学基金资助项目(81202712)~~

摘　　要：背景:透骨消痛胶囊是治疗骨性关节炎的临床验方,作用机制尚未完全阐明。尿激酶型纤溶酶原激活系统参与关节软骨的细胞外基质降解及关节滑膜增生,在骨性关节炎的病理过程中起着重要作用。目的:观察透骨消痛胶囊对膝骨性关节炎模型大鼠软骨中尿激酶型纤溶酶原激活系统的影响。方法:SD大鼠144只,随机取120只采用关节腔注射木瓜蛋白酶复制大鼠膝骨性关节炎模型,并随机分为模型组、壮骨关节丸组[1.2 g/(kg·d)]、透骨消痛胶囊低剂量组[0.092 g/(kg·d)]、透骨消痛胶囊中剂量组[0.184 g/(kg·d)]和透骨消痛胶囊高剂量组[0.368 g/(kg·d)],每组24只,每2周为1个疗程,中间休息2 d,共4个疗程。另取24只正常大鼠为空白组。每2个疗程后,处死一批实验动物,苏木精-伊红染色观察软骨组织病理改变;免疫组织化学反应观察尿激酶型纤溶酶原激活剂、尿激酶型纤溶酶原激活剂受体、纤溶酶原激活物抑制因子阳性表达情况;Western blot检测尿激酶型纤溶酶原激活剂、尿激酶型纤溶酶原激活剂受体、纤溶酶原激活物抑制因子蛋白表达情况。结果与结论:透骨消痛胶囊组和壮骨关节丸组的骨性关节炎大鼠关节软骨Mankin’s评分较模型组明显降低(P<0.01),具有时间依赖;免疫组织化学反应显示,透骨消痛胶囊组和壮骨关节丸组尿激酶型纤溶酶原激活剂、尿激酶型纤溶酶原激活剂受体的阳性率明显降低,而纤溶酶原激活物抑制因子明显升高,具有时间依赖。Western blot检测结果与免疫组织化学具有相同的趋势。提示透骨消痛胶囊可能通过调控尿激酶型纤溶酶原激活剂系统对骨性关节炎发挥防治作用。BACKGROUND：Tougu Xiaotong capsule is the clinical prescription for the treatment of osteoarthritis, however, its mechanism has not been fuly elucidated. Urokinase type plasminogen activator system which participated in the degradation of the extracelular matrix of articular cartilage and hyperplasia of joint synovium plays an important role in the pathological process of osteoarthritis. OBJECTIVE： To determine the effect ofTougu Xiaotong capsule on urokinase-type plasminogen activator system in knee cartilage tissues of knee osteoarthritis rats. METHODS： Of 144 Sprague-Dawley rats, 120 rats were randomly made into models of knee osteoarthritis via-inbsp;intra-articular injection of papain, and randomly assigned to model group,Zhuanggu Guanjie Wan group [1.2 g/（kg·d）], low-doseTougu Xiaotong capsule group [0.092 g/（kg·d）], moderate-doseTougu Xiaotong capsule group [0.184 g/（kg·d）] and high-doseTougu Xiaotong capsule group [0.368 g/（kg·d）]. Each group contained 24 rats. Every 2 weeks was considered as a course, with a 2-day interval, totaly 4 courses. The remaining 24 normal rats were included in the blank group. After every two courses, a batch of experimental animals was sacrificed. The pathological changes were observed folowing staining with hematoxylin and eosin. The positive cels of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitor were measured by immunohistochemistry. The protein levels of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitor were measured by western blot assay. RESULTS AND CONCLUSION：Mankin’s score was significantly lower in theTougu Xiaotong capsule group and Zhuanggu Guanjie Wan group compared with the model group （P 〉 0.01）, in a time-dependent manner. Immunohistochemical staining indicated that the positive cels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor were significant

关 键 词：实验动物 组织工程 透骨消痛胶囊 骨性关节炎 软骨组织 尿激酶型纤溶酶原激活剂 尿激酶型纤溶酶原激活剂受体 纤溶酶原激活剂抑制剂 国家自然科学基金 

分 类 号：R318[医药卫生—生物医学工程]